Ascendis Pharma A/S (NASDAQ:ASND) Trading Down 3.3% - What's Next?

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) was down 3.3% during mid-day trading on Tuesday . The company traded as low as $153.17 and last traded at $155.91. Approximately 340,340 shares were traded during trading, a decline of 29% from the average daily volume of 482,209 shares. The stock had previously closed at $161.15.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ASND. JPMorgan Chase & Co. increased their price target on Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an "overweight" rating in a report on Tuesday, March 18th. The Goldman Sachs Group raised their price target on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. UBS Group began coverage on shares of Ascendis Pharma A/S in a report on Tuesday, January 7th. They issued a "buy" rating and a $196.00 price target on the stock. Cantor Fitzgerald raised their price objective on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an "overweight" rating in a report on Tuesday, February 25th. Finally, Evercore ISI upped their target price on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an "outperform" rating in a research note on Tuesday, February 18th. Two research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $204.67.

Ascendis Pharma A/S Stock Performance

The stock has a 50 day moving average of $153.78 and a 200 day moving average of $138.97. The stock has a market capitalization of $10.01 billion, a P/E ratio of -23.12 and a beta of 0.54.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.32) by $0.64. On average, research analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Hedge Funds Weigh In On Ascendis Pharma A/S

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ASND. Point72 Asia Singapore Pte. Ltd. acquired a new position in Ascendis Pharma A/S during the 4th quarter worth $28,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Ascendis Pharma A/S during the third quarter valued at about $30,000. Jones Financial Companies Lllp lifted its holdings in Ascendis Pharma A/S by 394.0% in the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock worth $34,000 after purchasing an additional 197 shares during the period. Blue Trust Inc. grew its position in Ascendis Pharma A/S by 415.2% in the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock valued at $56,000 after buying an additional 328 shares in the last quarter. Finally, GAMMA Investing LLC increased its stake in Ascendis Pharma A/S by 58.0% during the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock valued at $80,000 after buying an additional 214 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.